Physicians' Academy for Cardiovascular Education

CETP inhibitor increases HDL-C significantly but does not reduce CV outcomes

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

Literature - Lincoff MA, Nicholls SJ, Riesmeyer JS, et al. - N Engl J Med 2017;376:1933-42

Main results


In the ACCELERATE study, treatment with evacetrapib compared with placebo was associated with an increase in the HDL-C and a reduction in LDL-C, but not with a reduction of CV outcomes.


Show references

Find this article online at NEJM

Share this page with your colleagues and friends: